Rapastinel
- Generic Name
- Rapastinel
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H31N5O6
- CAS Number
- 117928-94-6
- Unique Ingredient Identifier
- 6A1X56B95E
- Background
Rapastinel has been used in trials studying the treatment of Depressive Disorder, Major and Obsessive-Compulsive Disorder (OCD).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2019-12-27
- Lead Sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Target Recruit Count
- 658
- Registration Number
- NCT02943564
- Locations
- ๐บ๐ธ
Relaro Medical Trials, Dallas, Texas, United States
๐บ๐ธGreat Lakes Clinical Trials, Chicago, Illinois, United States
๐บ๐ธEarle Research, Houston, Texas, United States
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Target Recruit Count
- 429
- Registration Number
- NCT02943577
- Locations
- ๐บ๐ธ
Gulfcoast Clinical Research Center, Fort Myers, Florida, United States
๐บ๐ธInnova Clinical Trials Inc., Miami, Florida, United States
๐บ๐ธSun Valley Research Center, Imperial, California, United States
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2019-10-11
- Lead Sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Target Recruit Count
- 465
- Registration Number
- NCT02932943
- Locations
- ๐บ๐ธ
Southern California Research LLC., Beverly Hills, California, United States
๐บ๐ธATP Clinical Research Inc., Costa Mesa, California, United States
๐บ๐ธCollaborative Neuroscience Network, LLC, Garden Grove, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.